

Streptococcus pyogenes Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/S93A096DE4FCEN.html>

Date: March 2022

Pages: 40

Price: US\$ 2,000.00 (Single User License)

ID: S93A096DE4FCEN

Abstracts

Streptococcus pyogenes Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape.

Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant pain, swelling, and redness of infected area, fever, dizziness, difficulty breathing, dangerously low blood pressure, and a weak, rapid pulse. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcus pyogenes Infections - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Streptococcus pyogenes

Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Streptococcus pyogenes Infections - Overview
- Streptococcus pyogenes Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Streptococcus pyogenes Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development
- Cadila Healthcare Ltd
- Crestone Inc
- Olymvax Biopharmaceuticals Inc
- Recce Pharmaceuticals Ltd
- Wellstat Vaccines LLC
- Streptococcus pyogenes Infections - Drug Profiles
- (mupirocin calcium + neomycin sulfate + HT-61) - Drug Profile
- Product Description
- Mechanism Of Action
- CRS-0540 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies for Streptococcus pyogenes Infections - Drug Profile
- Product Description
- Mechanism Of Action
- RECCE-327 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Streptococcus Pyogenes Infections - Drug Profile
- Product Description

Mechanism Of Action

Streptococcus [serotype A] vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

streptococcus pyogenes (30-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

Streptococcus pyogenes vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

Streptococcus pyogenes vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

Streptococcus pyogenes Infections - Dormant Projects

Streptococcus pyogenes Infections - Discontinued Products

Streptococcus pyogenes Infections - Product Development Milestones

Featured News & Press Releases

Jul 20, 2021: Recce Pharmaceuticals announces lead synthetic anti-infective RECCE 327 demonstrates outstanding efficacy against necrotizing fasciitis 'flesh-eating' bacteria

Sep 05, 2019: Potential vaccine treats and prevents deadly streptococcal toxic shock

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Streptococcus pyogenes Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Streptococcus pyogenes Infections - Pipeline by Cadila Healthcare Ltd, 2022
Streptococcus pyogenes Infections - Pipeline by Crestone Inc, 2022
Streptococcus pyogenes Infections - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
Streptococcus pyogenes Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines LLC, 2022
Streptococcus pyogenes Infections - Dormant Projects, 2022
Streptococcus pyogenes Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Streptococcus pyogenes Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Streptococcus pyogenes Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/S93A096DE4FCEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S93A096DE4FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

